Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616264 | 0.80 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL29636861 | 0.77 | CDK1 (0.49) | ALDH1A1KDM4ESMN1; SMN2CDK1FGFR1 | |
| SCHEMBL602131 | 0.77 | CDK1 (0.49) | ALDH1A1KDM4ESMN1; SMN2CDK1FGFR1 | |
| SCHEMBL21522867 | 0.74 | PI4KA (0.39) | PI4KAPI4K2BPI4K2API4KBTP53 | |
| SCHEMBL743863 | 0.74 | KDM4E (0.36) | ALDH1A1KDM4ESMN1; SMN2CDK1FGFR1 | |
| SCHEMBL19968864 | 0.74 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBNPC1 | |
| SCHEMBL12985132 | 0.73 | KDM4E (0.32) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1496411 | 0.73 | CDK2 (0.46) | PI4KAPI4K2BPI4K2API4KBNPC1 | |
| SCHEMBL30332427 | 0.73 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBTP53 | |
| SCHEMBL16714533 | 0.73 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | PI4KA 3541/4885PI4K2B 4005/4885PI4K2A 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.